Roger Jeffs Sells 25,000 Shares of Liquidia (NASDAQ:LQDA) Stock

May 16, 2026 by InsiderTrades.com

Key Points

Liquidia CEO Roger Jeffs sold 25,000 shares on May 13 at an average price of $56.29, for proceeds of about $1.41 million. The transaction was made under a pre-arranged Rule 10b5-1 trading plan.
Jeffs has been active in selling shares recently, including multiple additional trades in May and April. Despite the sales, he still directly owns 1,248,095 shares valued at roughly $70.3 million.
Liquidia’s stock has rallied sharply, trading near its 52-week high of $59.75, while the company also reported stronger-than-expected quarterly results. Analysts remain generally positive, with several raising price targets and the stock carrying a Moderate Buy consensus rating.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) CEO Roger Jeffs sold 25,000 shares of the business's stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $56.29, for a total transaction of $1,407,250.00. Following the completion of the sale, the chief executive officer directly owned 1,248,095 shares in the company, valued at approximately $70,255,267.55. This represents a 1.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

MarketBeat Week in Review: 12/25 - 12/29

Roger Jeffs also recently made the following trade(s):

On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $57.04, for a total transaction of $1,426,000.00.
On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $41.50, for a total transaction of $1,037,500.00.
On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total transaction of $1,052,250.00.
On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total transaction of $1,002,500.00.
On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total transaction of $764,863.40.
On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total transaction of $1,003,500.00.
On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The stock was sold at an average price of $40.00, for a total transaction of $132,000.00.
On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total transaction of $1,256,387.28.
On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total transaction of $859,891.96.
On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total transaction of $1,003,000.00.

Liquidia Trading Down 4.0%

Shares of NASDAQ:LQDA opened at $56.93 on Friday. The company's 50-day moving average price is $39.70 and its two-hundred day moving average price is $35.94. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 1.84. Liquidia Corporation has a one year low of $11.85 and a one year high of $59.75. The stock has a market capitalization of $5.06 billion, a PE ratio of 406.67 and a beta of 0.41.

Liquidia: Court victory the awakening of an industry giant?

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million for the quarter, compared to analysts' expectations of $119.44 million. Liquidia's revenue for the quarter was up 4187.1% compared to the same quarter last year. On average, equities analysts forecast that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia in the fourth quarter valued at $25,000. Covestor Ltd increased its holdings in shares of Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company's stock valued at $42,000 after purchasing an additional 359 shares during the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Liquidia in the third quarter valued at $30,000. FNY Investment Advisers LLC acquired a new position in shares of Liquidia in the third quarter valued at $34,000. Finally, NewEdge Advisors LLC acquired a new position in shares of Liquidia in the second quarter valued at $25,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Liquidia in a research report on Tuesday, April 21st. Lifesci Capital raised shares of Liquidia to a "strong-buy" rating in a research report on Thursday, March 5th. Jefferies Financial Group reaffirmed a "buy" rating and set a $60.00 price target on shares of Liquidia in a research report on Monday. HC Wainwright upped their price target on shares of Liquidia from $55.00 to $67.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, BTIG Research upped their price target on shares of Liquidia from $50.00 to $59.00 and gave the stock a "buy" rating in a research report on Monday, May 11th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Liquidia currently has an average rating of "Moderate Buy" and an average target price of $49.33.

Read Our Latest Report on Liquidia

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: Liquidia’s first-quarter results beat Wall Street expectations on both earnings and revenue, reinforcing confidence that YUTREPIA is gaining commercial traction and that profitability is improving. Results: Liquidia Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts
Positive Sentiment: Several analysts raised estimates and price targets after the earnings report, including HC Wainwright boosting near-term EPS forecasts and keeping a Buy rating with a $67 target, which supports the bullish outlook on LQDA. Liquidia (LQDA) price target increased by 22.37% to 63.24
Positive Sentiment: Valuation-focused commentary highlighted that YUTREPIA-driven profitability and strong first-quarter performance could justify Liquidia’s recent share price strength if launch momentum continues. A Look At Liquidia (LQDA) Valuation After YUTREPIA Fueled Profitability And Strong First Quarter Results
Positive Sentiment: Zacks noted improving earnings estimate revisions, suggesting analysts see additional upside potential for Liquidia in the near term. Earnings Estimates Moving Higher for Liquidia Corporation (LQDA): Time to Buy?
Neutral Sentiment: Director Stephen Bloch sold 318,893 shares, a notable insider transaction, but it does not necessarily signal a change in the company’s operating outlook. Stephen Bloch Sells 318,893 Shares of Liquidia (NASDAQ:LQDA) Stock
Neutral Sentiment: One analyst lowered a longer-dated EPS estimate, showing there is still some disagreement on how quickly growth can scale over time. Liquidia stock and analyst reports

Liquidia Company Profile

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).